K-LYTE/CL 50 Rx
Generic Name and Formulations:
Potassium (as chloride) 50mEq; effervescent tabs for soln; citrus and fruit-flavor.
- Venoarterial ECMO Improves Survival to Transplant in Interstitial Lung Disease
- Mortality Increased With Liberal Oxygen Therapy in Acutely Ill Patients
- Tiotropium/Olodaterol Combination vs Tiotropium Alone for Severe COPD Exacerbations
Indications for K-LYTE/CL 50:
Hypokalemia, including that caused by diuretics. Digitalis intoxication without AV block.
Prophylaxis: 25mEq daily. Treatment: 50–100mEq daily in divided doses. Both, dissolve each tab in 6–8oz of water and sip slowly over 5–10 minutes after meals.
Hyperkalemia. Chronic renal disease. Acute dehydration. Heat cramps. Severe tissue destruction. Adrenal insufficiency. Familial periodic paralysis. Acidosis (potassium chloride products). Alkalosis (potassium bicarbonate products). Tablets: Esophageal compression due to enlarged left atrium. Decreased GI motility.
Discontinue if GI bleed, ulceration, or other disturbances occur. Renal or cardiac disease. Monitor potassium level, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers.
Hyperkalemia with ACE inhibitors, spironolactone, triamterene, amiloride, and potassium-containing salt substitutes. Anticholinergics, other agents that decrease GI motility increase risk of serious GI reactions with tablets.
Hyperkalemia, GI discomfort and irritation, diarrhea, rash (rare). Tablets: Esophageal and GI ulceration, bleeding, obstruction, perforation.
K-Lyte/Cl tabs—30, 100, 250; K-Lyte/Cl 50 tabs—30, 100